Basit öğe kaydını göster

dc.contributor.authorKutuk, Meryem Ozlem
dc.contributor.authorGuler, Gulen
dc.contributor.authorTufan, Ali Evren
dc.contributor.authorKutuk, Ozgur
dc.date.accessioned2019-06-02T12:24:18Z
dc.date.available2019-06-02T12:24:18Z
dc.date.issued2017
dc.identifier.issn1738-1088
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678489/
dc.identifier.urihttp://hdl.handle.net/11727/3388
dc.description.abstractOur case had hiccups arising in an adolescent with the attention deficit and hyperactivity disorder (ADHD) and conduct disorder (CD) after adding aripiprazole treatment to extended-release methylphenidate. Actually, antipsychotics are also used in the treatment of hiccups, but studies suggest that they can cause hiccups as well. Within 12 hours of taking 2.5 mg aripiprazole added to extended-release methylphenidate at a dose of 54 mg/day, 16-year-old boy began having hiccups in the morning, which lasted after 3-4 hours. As a result, aripiprazole was discontinued and methylphenidate was continued alone because we could not convince the patient to use another additional drug due to this side effect. Subsequently, when his behavior got worsened day by day, his mother administered aripiprazole alone again at the dose of 2.5 mg/day at the weekend and continued treatment because hiccup did not occur again. But when it was administered with methylphenidate on Monday, hiccup started again next morning and lasted one hour at this time. In conclusion, we concluded that concurrent use of methylphenidate and aripiprazole in this adolescent led to hiccups.en_US
dc.language.isoengen_US
dc.relation.isversionof10.9758/cpn.2017.15.4.410en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAripiprazoleen_US
dc.subjectCytochrome P-450 CYP2D6en_US
dc.subjectHiccupen_US
dc.subjectMethylphenidateen_US
dc.titleHiccup Due to Aripiprazole Plus Methylphenidate Treatment in an Adolescent with Attention Deficit and Hyperactivity Disorder and Conduct Disorder: A Case Reporten_US
dc.typeeditorialen_US
dc.relation.journalCLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCEen_US
dc.identifier.volume15en_US
dc.identifier.issue4en_US
dc.identifier.startpage410en_US
dc.identifier.endpage412en_US
dc.identifier.wos000415134200014en_US
dc.identifier.scopus2-s2.0-85032719578en_US
dc.contributor.pubmedID29073754en_US
dc.contributor.orcID0000-0002-2918-7871en_US
dc.contributor.orcID0000-0001-9854-7220en_US
dc.contributor.researcherIDAAI-9626-2021en_US
dc.contributor.researcherIDAAH-1671-2019en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster